Vasodilators In Cardiac Diseases
Introduction
Vasodilators are a class of medications that widen blood vessels by relaxing the smooth muscle in their walls, thereby increasing blood flow and reducing blood pressure. This physiological action makes them crucial in the management of various cardiac diseases, which are among the leading causes of morbidity and mortality worldwide. Understanding the mechanisms of action, clinical applications, and genetic influences on vasodilator response is vital for personalized medicine and improving patient outcomes.
Background
Cardiac diseases, including hypertension, coronary artery disease, and heart failure, are characterized by impaired cardiovascular function, often involving issues with blood vessel constriction and elasticity. Vasodilators counteract these issues by promoting vasodilation, which can alleviate symptoms, improve organ perfusion, and reduce the workload on the heart. The efficacy of these treatments can vary significantly among individuals, partly due to genetic factors influencing their biological pathways.
Biological Basis
Vasodilation is a complex physiological process regulated by multiple pathways. A primary mechanism involves the nitric oxide (NO) pathway, where NO acts as a potent vasodilator, promoting the relaxation of vascular smooth muscle cells. [1] Genetic variations at the endothelial nitric oxide synthase (NOS3) locus, which is involved in NO production, have been linked to brachial artery vasodilator function. [1] Similarly, the renin-angiotensin system (RAS) plays a critical role in regulating blood pressure and vascular tone. Polymorphisms within the RAS, such as those in the angiotensin-converting enzyme (ACE) gene or angiotensinogen (AGT) gene, can affect endothelium-dependent vasodilation and influence blood pressure responses . [2], [3] Enzymes like phosphodiesterase 5 (PDE5) also regulate vascular tone by degrading cyclic guanosine monophosphate (cGMP), a molecule involved in smooth muscle relaxation. [4] Other genes, such as the beta-1 adrenergic receptor gene (ADRB1), have been studied for their association with aerobic power in coronary artery disease [5] and the acetylcholine receptor M2 (CHRM2) gene polymorphism has been linked to heart rate recovery after exercise. [6]
Clinical Relevance
Vasodilators are cornerstones in the treatment of several cardiac conditions. In hypertension, they are used to lower blood pressure, thereby reducing the risk of stroke, heart attack, and kidney disease. [7] For coronary artery disease, vasodilators can improve blood flow to the heart muscle, alleviating angina symptoms and improving exercise tolerance . [8], [9] In heart failure, they help reduce the heart's workload by decreasing peripheral vascular resistance and venous return. [4] Endothelial dysfunction, assessed through brachial artery flow-mediated dilation (FMD), is recognized as an early indicator and precursor of overt cardiovascular disease, highlighting the importance of maintaining healthy vascular function . [4], [10], [11] Genetic variations can influence an individual's response to exercise and their risk for developing cardiovascular conditions. [4] For instance, common genetic variants in genes such as NOS3 and ESR1 show modest associations with subclinical atherosclerosis. [12]
Social Importance
Cardiac diseases represent a significant global health burden, impacting millions of lives and imposing substantial economic costs. The effective use of vasodilators contributes to improving public health by extending life expectancy, enhancing the quality of life for patients, and reducing healthcare expenditures associated with managing advanced cardiovascular complications. The study of genetic variations influencing vasodilator response, such as those impacting lipid concentrations [1], [13] or early markers of disease [14] offers the potential for personalized therapeutic strategies, optimizing drug selection and dosing to maximize benefits and minimize adverse effects for each patient.
Methodological and Statistical Constraints
Studies investigating the genetic basis of traits relevant to vasodilators in cardiac diseases faced limitations in statistical power, particularly when attempting to detect modest genetic effects amid extensive multiple statistical testing inherent in genome-wide association studies (GWAS). [4] While the research had sufficient power to identify associations explaining 4% or more of total phenotypic variation, smaller, yet potentially clinically significant, genetic influences on cardiac function or vascular traits may have been overlooked. [4] This constraint means that the absence of genome-wide significance for certain associations does not definitively rule out a genetic role in the studied traits, underscoring the challenge of fully capturing the genetic architecture of complex cardiovascular phenotypes. [4]
A fundamental challenge in identifying genetic associations relevant to vasodilator efficacy or cardiac disease susceptibility is the need for external replication to validate findings and distinguish true positive genetic associations from those that may be spurious. [10] Some reported associations, despite moderate statistical support, are considered exploratory and require examination in independent cohorts, especially given the partial coverage of genetic variation by the genotyping platforms used. [10] This limitation highlights the potential for inflated effect sizes or false-positive results without corroboration, impacting the confidence in prioritizing single nucleotide polymorphisms (SNPs) for follow-up investigations aimed at understanding vasodilator mechanisms. [10]
Phenotypic Measurement and Cohort Specificity
The characterization of cardiac phenotypes, such as echocardiographic dimensions, which are relevant to the application of vasodilators, presented challenges due to the methodology of data collection. [4] Averaging echocardiographic traits across multiple examinations, while intended to reduce regression dilution bias, spanned up to twenty years and utilized different echocardiographic equipment, which could introduce measurement misclassification and variability over time. [4] Furthermore, this averaging implicitly assumes a consistent influence of genes and environmental factors across a wide age range, potentially masking age-dependent genetic effects that could be crucial for understanding the etiology of cardiac conditions and response to vasodilators. [4]
The generalizability of genetic findings related to cardiac traits and, by extension, to the efficacy or response to vasodilators, is limited by the demographic homogeneity of the study cohorts. [4] The study populations were exclusively composed of individuals of white, European descent. [4] Consequently, the applicability of the observed genetic associations and their implications for vasodilators in cardiac diseases to other ethnicities or populations remains unknown. [4] This demographic specificity underscores the need for diverse cohort studies to determine if these genetic influences are universal or population-specific, which is vital for equitable clinical translation and personalized medicine approaches. [4]
Environmental Interactions and Knowledge Gaps
A significant gap in understanding the full genetic landscape influencing cardiac traits pertinent to vasodilators stems from the lack of comprehensive investigation into gene-environment interactions. [4] Genetic variants may influence phenotypes in a context-specific manner, being modulated by environmental influences. [4] For instance, previous research has indicated that associations of genes like ACE and AGTR2 with left ventricular mass can vary significantly based on environmental factors such as dietary salt intake. [4] The absence of such analyses means the full context in which genetic variants influence vasodilator response and cardiac traits is not fully characterized, potentially leading to an incomplete understanding of their biological mechanisms. [4]
While genetic studies identify specific loci, the broader etiology of cardiac diseases and the variable response to treatments like vasodilators often involves complex interactions that remain largely uncharacterized. [4] The interplay between genetic predispositions and environmental exposures typically explains a substantial portion of phenotypic variability, commonly referred to as "missing heritability". [4] The current research, by not delving into these interactions, leaves open questions about how lifestyle, diet, or other external factors modify genetic influences on cardiac traits relevant to vasodilators, which is crucial for developing personalized therapeutic strategies and fully understanding disease etiology. [4]
Variants
Genetic variations play a crucial role in influencing cardiovascular health, affecting processes from vascular tone to arterial remodeling, and consequently, the efficacy of vasodilators used in cardiac diseases. Several key genetic regions and their variants have been identified for their associations with various aspects of cardiovascular function and disease susceptibility.
Variants within or near the CDKN2B-AS1 gene, including rs2891168, rs10757274, and rs1333047, are associated with an increased risk of coronary artery disease and myocardial infarction, influencing cell cycle regulation and cellular senescence in vascular tissues. These changes can contribute to arterial stiffness and impact the blood vessels' ability to dilate effectively in response to physiological signals or therapeutic interventions. [13] Similarly, variants rs55730499 and rs140570886 in the LPA gene are strongly linked to elevated levels of lipoprotein(a), a known risk factor for atherosclerosis and thrombotic events, which can impair endothelial function and reduce the responsiveness to vasodilatory drugs. The PHACTR1 gene, particularly with its rs9349379 variant, is involved in regulating vascular smooth muscle cell function and arterial integrity, and its variations can affect the development of conditions like fibromuscular dysplasia, thereby altering vascular remodeling and the overall capacity for vasodilation. [15]
The ALDH2 gene, through its rs671 variant, impacts the metabolism of aldehydes, which are toxic byproducts of alcohol metabolism and oxidative stress. Individuals with reduced ALDH2 activity due to this variant may experience heightened oxidative stress and endothelial dysfunction, leading to impaired vascular elasticity and a diminished response to vasodilators . Concurrently, the rs12190287 variant, located in a region encompassing both TCF21 and TARID, is implicated in coronary artery disease. TCF21 is a transcription factor critical for vascular smooth muscle cell differentiation and coronary artery development, and its genetic variations can lead to altered vascular wall structure and increased susceptibility to atherosclerosis, influencing the effectiveness of vasodilators in managing cardiac conditions. [16]
In the context of direct vascular regulation, the PRMT5P1 - EDNRA region, with variants like rs73855814 and rs6537481, is of significant interest as EDNRA encodes the endothelin receptor type A, a key mediator of vasoconstriction. Variations here can affect the balance between vasoconstriction and vasodilation, influencing blood pressure regulation and the therapeutic response to vasodilators. [17] Furthermore, genes involved in growth factor signaling, such as PDGFDDN (rs2128739, rs2839812) and FLT1 (rs75419986), play crucial roles in vascular remodeling and angiogenesis. Polymorphisms in platelet-derived growth factor and vascular endothelial growth factor pathways are significantly associated with cardiac allograft vasculopathy, underscoring their broad impact on vascular health and disease progression, directly affecting how blood vessels dilate or constrict .
The MAT2A gene, including its rs2028900 variant, is essential for methionine metabolism and the production of S-adenosylmethionine (SAM), a vital molecule for numerous cellular processes, including epigenetic modifications. Disruptions in this pathway can lead to endothelial dysfunction and arterial stiffening, potentially diminishing the effectiveness of vasodilators . Lastly, the region spanning HDAC9 and TWIST1, with the rs2107595 variant, is associated with various vascular diseases, including large artery stroke. HDAC9 (Histone Deacetylase 9) is involved in epigenetic regulation that controls vascular smooth muscle cell differentiation and arterial remodeling, impacting the mechanical properties of blood vessels and their responsiveness to dilatory signals, thereby influencing the management of cardiac diseases with vasodilators. [18]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs2891168 rs10757274 rs1333047 |
CDKN2B-AS1 | coronary artery disease myocardial infarction asthma, cardiovascular disease Beta blocking agent use measurement vasodilators used in cardiac diseases use measurement |
| rs671 | ALDH2 | body mass index erythrocyte volume mean corpuscular hemoglobin concentration mean corpuscular hemoglobin coronary artery disease |
| rs55730499 rs140570886 |
LPA | coronary artery disease parental longevity stroke, type 2 diabetes mellitus, coronary artery disease lipoprotein A measurement, apolipoprotein A 1 measurement lipoprotein A measurement, lipid or lipoprotein measurement |
| rs9349379 | PHACTR1 | coronary artery disease migraine without aura, susceptibility to, 4 migraine disorder myocardial infarction pulse pressure measurement |
| rs12190287 | TARID, TCF21 | coronary artery disease stroke, coronary artery disease large artery stroke, coronary artery disease serum creatinine amount glomerular filtration rate |
| rs73855814 rs6537481 |
PRMT5P1 - EDNRA | vasodilators used in cardiac diseases use measurement drug use measurement, coronary artery disease heart disease occlusion precerebral artery |
| rs2128739 rs2839812 |
PDGFDDN | coronary artery disease angina pectoris chronic obstructive pulmonary disease, coronary artery disease cardiovascular disease vasodilators used in cardiac diseases use measurement |
| rs75419986 | FLT1 | aspirin use measurement angina pectoris Antithrombotic agent use measurement vasodilators used in cardiac diseases use measurement |
| rs2028900 | MAT2A | basophil count prostate carcinoma angina pectoris vasodilators used in cardiac diseases use measurement prostate cancer |
| rs2107595 | HDAC9 - TWIST1 | coronary artery disease Ischemic stroke pulse pressure measurement stroke systolic blood pressure |
Defining Vasodilator Function and Endothelial Health
Vasodilator function refers to the intrinsic ability of blood vessels to widen, a crucial physiological process for regulating blood flow and maintaining cardiovascular homeostasis. In the context of cardiac diseases, the operational definition often centers on the capacity of the vascular endothelium to release vasodilatory substances, primarily nitric oxide, in response to stimuli. This endothelium-dependent vasodilation is precisely measured by flow-mediated dilation (FMD) of the brachial artery, which quantifies the percentage change in arterial diameter from a baseline measurement.. [4] Conceptually, FMD serves as a vital intermediate phenotype, bridging traditional cardiovascular risk factors with the development of overt cardiovascular disease (CVD) by reflecting the overall health and functional integrity of the vascular endothelium.. [4]
Measurement and Clinical Significance of Flow-Mediated Dilation
The measurement of brachial artery FMD involves a standardized non-invasive ultrasound technique. After establishing a baseline brachial artery diameter, blood flow is occluded for five minutes using a forearm cuff, followed by its release, which induces reactive hyperemia. FMD is then calculated as the percent change in diameter from the baseline to one minute post-occlusion, using the formula: 100 * ([hyperemic diameter at 1 minute - baseline diameter] / baseline diameter).. [4] Impaired FMD, indicative of endothelial dysfunction, is a significant diagnostic criterion, having emerged as a fundamental component in the pathogenesis of atherosclerosis and a robust precursor of overt CVD.. [4] Clinically, peripheral vascular endothelial function testing, specifically FMD, serves as a noninvasive indicator of coronary artery disease and provides additive value to other cardiovascular risk prediction tools, such as the ankle-brachial pressure index, in conditions like peripheral arterial disease.. [11]
Terminology and Genetic Underpinnings of Vasodilator Capacity
Key terminology in this domain includes "endothelium-dependent vasodilation," which describes the relaxation of blood vessels mediated by the endothelium, and "flow-mediated dilation" (FMD), the most common operational measure of this process. The term "endothelial dysfunction" signifies an impairment in this critical vasodilator capacity, recognized as a central mechanism in the development and progression of various cardiac diseases.. [4] Furthermore, the capacity for vasodilation is influenced by genetic factors, with studies identifying common genetic variations at loci such as the endothelial nitric oxide synthase gene and within the renin-angiotensin system that are associated with individual differences in brachial artery vasodilator function in the general population.. [1] These genetic correlates underscore the heritable nature of vascular traits and provide insights into the molecular pathways governing vasodilator capacity.. [19]
Pharmacogenetics of Vasodilators in Cardiac Diseases
Vasodilators are a cornerstone in the management of various cardiac conditions, including hypertension, heart failure, and coronary artery disease, by reducing vascular resistance and improving cardiac function. The effectiveness and safety of these medications can vary significantly among individuals, partly due to genetic differences that influence drug metabolism, drug targets, and downstream physiological pathways. Pharmacogenetics aims to elucidate these genetic underpinnings to enable more personalized and effective therapeutic strategies.
Genetic Variation Affecting Drug Targets and Vasodilatory Pathways
Genetic polymorphisms can profoundly influence the function of drug targets and key components within the vasodilatory pathways, thereby altering therapeutic responses. For instance, variants in genes encoding components of the Renin-Angiotensin System (RAS) are critical. Polymorphisms in the ACE gene, such as the insertion/deletion (I/D) polymorphism, have been associated with endothelium-dependent vasodilation and left ventricular mass in individuals with systemic hypertension, indicating how genetic makeup can modulate fundamental vascular responses. [20] Similarly, variants in the AGT gene, which codes for angiotensinogen, show associations with left ventricular mass and function, impacting the overall cardiac remodeling process that vasodilators aim to mitigate. [21] Such genetic variations can predict an individual's intrinsic vascular tone and their potential response to RAS-modulating vasodilators like ACE inhibitors or angiotensin receptor blockers (ARBs).
Beyond the RAS, genetic variation at the endothelial nitric oxide synthase (NOS3) locus is strongly related to brachial artery vasodilator function, a direct measure of vascular health. [1] NOS3 is crucial for producing nitric oxide, a potent endogenous vasodilator, and polymorphisms can affect its expression or activity, thereby influencing the efficacy of nitric oxide-dependent vasodilators. Furthermore, the PDE5A gene, encoding phosphodiesterase 5A, plays a role in cGMP signaling, a pathway targeted by many vasodilators. Angiotensin II has been shown to increase PDE5A expression in vascular smooth muscle cells, which antagonizes cGMP signaling. [17] Genetic variants in PDE5A could thus impact the effectiveness of PDE5 inhibitors, a class of vasodilators. These target and pathway-related polymorphisms represent significant determinants of how individuals respond to vasodilator therapies.
Impact of Genetic Variants on Pharmacodynamic Responses
Genetic variations can directly affect the pharmacodynamic responses to vasodilators, influencing both their efficacy and the likelihood of adverse reactions. For instance, common genetic variation at the NOS3 locus is linked to brachial artery vasodilator function, a key physiological parameter reflecting vascular endothelial health and responsiveness to vasodilatory stimuli. [1] Individuals with certain NOS3 genotypes might exhibit inherently different baseline endothelial function, which could predict their response to drugs that enhance nitric oxide bioavailability or mimic its effects. Similarly, polymorphisms within the renin-angiotensin system have been observed to alter endothelium-dependent vasodilation in normotensive subjects, suggesting a genetic predisposition to varying vascular reactivity. [2]
These genetic influences extend to broader cardiovascular phenotypes relevant to vasodilator therapy. For example, specific polymorphisms alter the acute blood pressure response to aerobic exercise among men with hypertension, indicating a genetic component to dynamic vascular regulation. [20] Such pharmacodynamic differences, driven by genetic variants, can lead to variable reductions in blood pressure, improvements in cardiac output, or changes in left ventricular dimensions following vasodilator administration. Understanding these genetic effects on physiological responses is crucial for anticipating how a patient's cardiovascular system will react to vasodilator treatment, potentially guiding dose adjustments or selection of alternative agents to optimize outcomes and minimize side effects.
Future Directions for Personalized Vasodilator Prescribing
The insights garnered from pharmacogenetic research, particularly through genome-wide association studies, hold significant promise for advancing personalized prescribing of vasodilators. While current analyses, such as those identifying associations between specific genes (ACE, AGT, AGTR1, NOS3, VEGF) and cardiac or vascular phenotypes, are often considered exploratory, they lay the groundwork for future clinical implementation. [4] Identifying genetic markers associated with favorable responses or increased risks of adverse events can eventually inform drug selection and dosing strategies.
The long-term goal is to integrate genetic information into clinical guidelines, allowing clinicians to tailor vasodilator therapy based on an individual's unique genetic profile. For example, knowing a patient's NOS3 genotype might predict their responsiveness to nitric oxide-enhancing drugs, while ACE or AGTR1 variants could guide the choice between different classes of RAS inhibitors. While direct dosing recommendations based on specific genotypes are still evolving, the continuous accumulation of evidence regarding gene-drug interactions for vasodilators points towards a future where genetic testing could aid in optimizing treatment for cardiac diseases, moving beyond a "one-size-fits-all" approach to truly personalized medicine.
Nitric Oxide-cGMP Signaling and Vascular Smooth Muscle Relaxation
The primary mechanism of many vasodilators involves the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) pathway, crucial for vascular smooth muscle relaxation. Genetic variation at the endothelial nitric oxide synthase (eNOS) locus has been linked to brachial artery vasodilator function, highlighting its role in maintaining vascular health. [1] Endothelial cells release NO, which then diffuses into adjacent vascular smooth muscle cells, activating soluble guanylate cyclase to produce cGMP. This increase in intracellular cGMP leads to downstream signaling that promotes vasodilation by decreasing intracellular calcium levels and modulating contractile protein activity.
However, this critical pathway can be antagonized by other regulatory systems, particularly the Renin-Angiotensin System (RAS). Angiotensin II, a potent vasoconstrictor, has been shown to increase the expression of phosphodiesterase 5A (PDE5A) in vascular smooth muscle cells. [17] PDE5A actively degrades cGMP, thereby reducing its concentration and counteracting the vasodilatory effects, contributing to the contracted state of blood vessels. [22] This interaction represents a crucial point of crosstalk where systemic neurohumoral factors can directly modulate local NO-cGMP signaling, influencing overall vascular tone and blood pressure regulation.
Neurohumoral Modulation and Cellular Ion Homeostasis
Beyond direct NO-cGMP interactions, several neurohumoral and ion channel pathways significantly influence vascular and cardiac function, impacting the efficacy of vasodilators. Polymorphisms within the Renin-Angiotensin System genes are associated with endothelium-dependent vasodilation, suggesting a genetic predisposition to altered vascular responses. [2] Furthermore, Angiotensin II plays a broader role in cardiovascular pathology, with angiotensinogen gene variants showing associations with left ventricular mass and function. [21] This indicates a complex interplay where genetic predispositions within neurohumoral systems can influence both vascular function and cardiac remodeling.
Intracellular ion homeostasis is also pivotal for both vasodilation and myocardial excitability. The CFTR chloride channel, for instance, has been found to alter the mechanical properties and cAMP-dependent chloride transport in mouse aortic smooth muscle cells, with its expression and activity also observed in human endothelia. [23] Dysregulation of ion channels like the ryanodine receptor (RyR2) can lead to severe cardiac conditions; mutations in the cardiac RyR2 gene are known to underlie catecholaminergic polymorphic ventricular tachycardia, representing a significant channelopathy. [24] These mechanisms underscore how cellular ion balance, regulated by specific channels, is intrinsically linked to both vascular smooth muscle function and cardiac rhythm, influencing the overall cardiovascular response to disease and therapy.
Cellular Migration, Growth, and Myocardial Remodeling Pathways
The regulation of cellular processes such as migration and growth in vascular and cardiac tissues is critical in the progression of cardiac diseases and the context of vasodilator therapy. The neuronal chemorepellent Slit2 has been identified to inhibit vascular smooth muscle cell migration by suppressing the activation of small GTPase Rac1. [25] This mechanism highlights a regulatory pathway that, if dysregulated, could contribute to vascular remodeling and stiffness, thereby affecting vasodilator efficacy. The mitogen-activated protein kinase (MAPK) pathway is another fundamental signaling cascade involved in cellular growth and differentiation, with its activation affected by factors such as age and acute exercise in human skeletal muscle. [4] The human tribbles protein family further controls MAPK cascades, indicating complex regulatory layers within these pathways. [26]
Myocardial remodeling, particularly cardiac hypertrophy, involves distinct gene regulation and protein expression patterns. Parallel gene expressions of IL-6 and BNP are observed during cardiac hypertrophy complicated with diastolic dysfunction. [27] Similarly, heat shock protein expression, including HSPA8, is noted in genetically and non-genetically hypertrophied hearts, with HSPA8 specifically associated with left ventricular mass. [28] These pathways collectively demonstrate how intricate signaling and regulatory mechanisms govern cell behavior and tissue structure in the cardiovascular system, which are often targets or consequences in the use of vasodilators for cardiac diseases.
Metabolic Pathways and Systemic Cardiovascular Risk Factors
Metabolic pathways play a fundamental role in systemic cardiovascular health and disease, influencing the overall environment in which vasodilators act. Lipid metabolism, for instance, is profoundly affected by genetic variations. Common single nucleotide polymorphisms (SNPs) in 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) are known to affect the alternative splicing of exon 13, influencing cholesterol biosynthesis via the mevalonate pathway. [29] This enzyme's activity is crucial for lipid regulation, and its modulation can impact arterial health. Furthermore, genes like ANGPTL3 regulate lipid metabolism, and variations in ANGPTL4 can lead to reduced triglycerides and increased high-density lipoprotein (HDL) levels. [30] A null mutation in human APOC3 has been shown to confer a favorable plasma lipid profile and apparent cardioprotection, underscoring the direct link between lipid metabolism and cardiovascular outcomes. [31]
The intricate regulation of lipid and energy metabolism involves various transcription factors and enzymes. SREBP-2 defines a potential link between isoprenoid and adenosylcobalamin metabolism, highlighting interconnected metabolic networks. [32] Common genetic variants within the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids, indicating genetic influence over fundamental lipid components. [33] Additionally, sortilin/neurotensin receptor-3 binds to and mediates the degradation of lipoprotein lipase, a key enzyme in triglyceride metabolism. [34] These metabolic pathways are critical determinants of cardiovascular risk, and their dysregulation can necessitate the use of vasodilators to manage the ensuing cardiac complications.
Genetic Modulators of Endothelial Function and Cardiovascular Risk
Genetic variations play a crucial role in influencing the body's intrinsic vasodilator function, which is fundamental to cardiovascular health. For instance, common genetic variations at the endothelial nitric oxide synthase (eNOS) locus are associated with brachial artery vasodilator function in the general population. Understanding these genetic predispositions can help predict an individual's baseline vascular health and potential susceptibility to cardiac conditions. [4] Similarly, polymorphisms within the renin-angiotensin system (RAS) are linked to endothelium-dependent vasodilation, even in individuals with normal blood pressure. [2] These genetic insights are valuable for identifying individuals at higher risk for cardiovascular dysfunction, contributing to early risk stratification and potentially informing preventive strategies before overt disease manifestation.
Diagnostic and Prognostic Utility in Cardiac Assessment
Assessment of endothelial function, particularly in the brachial artery, offers significant diagnostic and prognostic value in cardiac care. Research indicates that brachial artery endothelial function is associated with echocardiographic dimensions and responses to treadmill exercise. [4] These associations highlight the utility of evaluating vasodilator function as a marker for overall cardiovascular health, potentially aiding in the early detection of structural cardiac changes or impaired exercise capacity. By integrating these functional and genetic markers, clinicians can gain a more comprehensive understanding of disease progression and predict long-term implications for patients with or at risk of cardiac diseases.
Personalized Approaches to Cardiac Disease Management
The understanding of genetic influences on vasodilation has direct implications for personalized medicine approaches in cardiac disease management. Given that genetic variations in systems like eNOS and RAS affect how the body regulates blood vessel tone, these insights can inform treatment selection for therapies that modulate vasodilation. [4] Tailoring treatment strategies based on an individual's genetic profile may optimize the efficacy of vasodilator-based interventions, potentially improving patient outcomes and minimizing adverse effects. This personalized approach facilitates more precise risk stratification and helps in designing targeted prevention strategies for high-risk individuals.
References
[1] Kathiresan S, et al. "Common genetic variation at the endothelial nitric oxide synthase locus and relations to brachial artery vasodilator function in the community." Circulation, vol. 112, 2005, pp. 1419-1427.
[2] Kurland L, et al. "Polymorphisms in the renin-angiotensin system and endothelium-dependent vasodilation in normotensive subjects." Clin Physiol, vol. 21, 2001, pp. 343-349.
[3] Blanchard BE, et al. "RAAS polymorphisms alter the acute blood pressure response to aerobic exercise among men with hypertension." Eur J Appl Physiol, vol. 97, 2006, pp. 26-33.
[4] Vasan RS, et al. "Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study." BMC Med Genet, vol. 8, Suppl 1, 2007, p. S2.
[5] Defoor J, et al. "The CAREGENE study: polymorphisms of the beta1-adrenoceptor gene and aerobic power in coronary artery disease." Eur Heart J, vol. 27, 2006, pp. 808-816.
[6] Hautala AJ, et al. "Heart rate recovery after maximal exercise is associated with acetylcholine receptor M2 (CHRM2) gene polymorphism." Am J Physiol Heart Circ Physiol, vol. 291, 2006, pp. H459-H466.
[7] Messerli FH, et al. "Serum uric acid in essential hypertension: an indicator of renal vascular involvement." Ann Intern Med, vol. 93, 1980, pp. 817-821.
[8] Fuster V, et al. "The pathogenesis of coronary artery disease and the acute coronary syndromes (1)." N Engl J Med, vol. 326, 1992, pp. 242-250.
[9] Kuvin JT, et al. "Peripheral vascular endothelial function testing as a noninvasive indicator of coronary artery disease." J Am Coll Cardiol, vol. 38, 2001, pp. 1843-1849.
[10] Benjamin EJ, et al. "Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study." Circulation, vol. 109, 2004, pp. 613-619.
[11] Brevetti G, et al. "Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index." Circulation, vol. 108, 2003, pp. 2093-2098.
[12] O'Donnell CJ, et al. "Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study." BMC Med Genet, vol. 8, Suppl 1, 2007, p. S4.
[13] Willer CJ, et al. "Newly identified loci that influence lipid concentrations and risk of coronary artery disease." Nat Genet, vol. 40, no. 2, 2008, pp. 161-169.
[14] Wallace C, et al. "Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia." Am J Hum Genet, vol. 82, no. 1, 2008, pp. 139-149.
[15] Kathiresan, Sekar, et al. "Common variants at 30 loci contribute to polygenic dyslipidemia." Nature Genetics, vol. 41, no. 1, 2009, pp. 56-65.
[16] Dupuis, Jonathan, et al. "Genome scan of systemic biomarkers of vascular inflammation in the Framingham Heart Study: evidence for susceptibility loci on 1q." Atherosclerosis, vol. 182, no. 2, 2005, pp. 307-314.
[17] Kim, D, et al. "Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling." Journal of Molecular and Cellular Cardiology, vol. 38, no. 1, 2005, pp. 175-184.
[18] Kardia, Sharon L. "Context-dependent genetic effects in hypertension." BMC Medical Genetics, vol. 8, no. Suppl 1, 2007, p. S10.
[19] Mitchell, G. F. et al. "Local Shear Stress and Brachial Artery Flow-Mediated Dilation: The Framingham Heart Study." Hypertension, vol. 44, 2004, pp. 134-139.
[20] Celentano, A, et al. "Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension." American Journal of Cardiology, vol. 83, no. 8, 1999, pp. 1196-1200.
[21] Tang, W, et al. "Associations between angiotensinogen gene variants and left ventricular mass and function in the HyperGEN study." American Heart Journal, vol. 143, no. 5, 2002, pp. 854-860.
[22] Lin, C. S., et al. "Expression, distribution and regulation of phosphodiesterase 5." Curr Pharm Des, vol. 12, no. 27, 2006, pp. 3439-3457.
[23] Robert, R., et al. "Disruption of CFTR chloride channel alters mechanical properties and cAMP-dependent Cl- transport of mouse aortic smooth muscle cells." J Physiol (Lond), vol. 568, no. Pt 2, 2005, pp. 483-495.
[24] Benkusky, N. A., et al. "Ryanodine receptor channelopathies." Biochem Biophys Res Commun, vol. 322, no. 4, 2004, pp. 1280-1285.
[25] Liu, D., et al. "Neuronal chemorepellent Slit2 inhibits vascular smooth muscle cell migration by suppressing small GTPase Rac1 activation." Circ Res, vol. 98, no. 4, 2006, pp. 480-489.
[26] Kiss-Toth, E., et al. "Human tribbles, a protein family controlling mitogen-activated protein kinase cascades." J Biol Chem, vol. 279, no. 41, 2004, pp. 42703-42708.
[27] Haugen, E., et al. "Parallel gene expressions of IL-6 and BNP during cardiac hypertrophy complicated with diastolic dysfunction in spontaneously hypertensive rats." Int J Cardiol, 2006.
[28] Iwabuchi, K., et al. "Heat shock protein expression in hearts hypertrophied by genetic and nongenetic hypertension." Heart Vessels, vol. 13, no. 1, 1998, pp. 30-39.
[29] Burkhardt, R., et al. "Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13." Arterioscler Thromb Vasc Biol, 2009.
[30] Koishi, R., et al. "Angptl3 regulates lipid metabolism in mice." Nat Genet, vol. 30, no. 2, 2002, pp. 151-157.
[31] Pollin, T. I., et al. "A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection." Science, vol. 322, no. 5906, 2008, pp. 1702-1705.
[32] Murphy, C., et al. "Regulation by SREBP-2 defines a potential link between isoprenoid and adenosylcobalamin metabolism." Biochem Biophys Res Commun, vol. 355, no. 2, 2007, pp. 359-364.
[33] Schaeffer, L., et al. "Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids." Hum Mol Genet, vol. 15, no. 10, 2006, pp. 1745-1756.
[34] Nielsen, M. S., et al. "Sortilin/neurotensin receptor-3 binds and mediates degradation of lipoprotein lipase." J Biol Chem, vol. 274, no. 13, 1999, pp. 8832-8836.